- Approved
- Type
- New molecular entity
- FDA-approved use
- To treat the neurological symptoms of Type 3 Gaucher diseaseWording from FDA's list of novel approvals.
At a glance
Infilbray (venglustat) is an oral glucosylceramide synthase inhibitor. FDA approved it on November 18, 2026 to treat the neurological symptoms of Type 3 Gaucher disease. The sources provided contain no trial in Gaucher disease. The supplied trials in other conditions showed no benefit, and the most common adverse events were constipation and nausea. It has no boxed warning.
What it is and how it works
Venglustat blocks glucosylceramide synthase, the enzyme that makes glucosylceramide. This is substrate reduction: it lowers production of the lipid rather than replacing the deficient enzyme. It is brain penetrant, and in Parkinson's disease with GBA mutations it lowered glucosylceramide in plasma and cerebrospinal fluid in a dose-dependent way. Enzyme replacement therapy does not reach the brain well, so a brain-penetrant oral drug targets a different gap.
Pivotal trials
STAGED-PKD NCT03523728
- Design
- Two-stage, multicenter, double-blind, randomized, placebo-controlled phase 2/3 trial in ADPKD. This is not the approved indication.
- Patients
- 236 adults in stage 1 and 242 in stage 2, with ADPKD at risk of rapid progression (Mayo imaging class 1C to 1E, eGFR 30 to 89.9).
- Compared with
- Placebo. Stage 1 tested two venglustat doses and stage 2 tested the higher dose.
- Primary endpoint
- Rate of change in total kidney volume over 18 months (stage 1) and eGFR slope over 24 months (stage 2).
Result
Venglustat had no effect on the annualized rate of change in total kidney volume. The eGFR declined faster than with placebo. The trial was stopped early for lack of efficacy after a futility analysis.
- Other results
- Secondary end points included eGFR slope at 18 months, kidney volume change in stage 2, pain, fatigue and safety. The abstract gives no separate results for them.
- Safety in the trial
- The abstract does not report adverse event rates. The higher dose was chosen for stage 2 because it was safe and well tolerated in stage 1.
EvidencePulse™
Ask about Infilbray
The question that opens in EvidencePulse
How does Infilbray (venglustat) compare with the alternatives (Imiglucerase, Velaglucerase alfa, Eliglustat) for the neurological symptoms of Type 3 Gaucher disease? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.
Ask in EvidencePulseFree to try, more with 2MM+.
Deep research is a core feature of 2MM Max.
MOVES-PD part 2 NCT02906020
- Design
- International, double-blind, randomized, placebo-controlled phase 2 trial over 52 weeks in GBA1-associated Parkinson's disease. This is not the approved indication.
- Patients
- 221 adults aged 18 to 80 with early Parkinson's disease (Hoehn and Yahr stage 2 or lower) and one or more GBA1 variants; 110 received venglustat and 111 placebo.
- Compared with
- Matching placebo.
- Primary endpoint
- Change from baseline to week 52 in the combined MDS-UPDRS parts II and III score.
Result
The mean change was 7.29 with venglustat and 4.71 with placebo, a difference of 2.58 (95% CI -1.10 to 6.27; P=0.17). Higher scores mean worse function, so there was no benefit.
- Other results
- Not reported in the abstract.
- Safety in the trial
- Constipation and nausea were each reported by 23 (21%) venglustat patients and 8 (7%) placebo patients. Serious adverse events occurred in 12 (11%) in each group. One venglustat patient died of cardiopulmonary arrest judged unrelated.
Safety signals
There is no boxed warning. The sources supplied do not include the label's warnings and precautions, so they are not summarized here. In a Parkinson's disease trial, constipation and nausea were the most common adverse events and were more frequent with venglustat than with placebo. Serious adverse events occurred in the same number of patients in each group. One death occurred in the venglustat group, from cardiopulmonary arrest judged unrelated. In an early dose-escalation study, two patients stopped treatment because of confusional state and panic attack. Most adverse events there were mild or moderate.
What it competes with
Type 3 Gaucher disease is managed mainly with lifelong treatment that targets the systemic features. These treatments do not clearly address the neurological features.
- ImigluceraseEnzyme replacement therapy for Gaucher disease. It treats systemic features but does not reach the brain well.
- Velaglucerase alfaEnzyme replacement therapy for Gaucher disease. It has the same limited brain penetration as other enzyme therapies.
- EliglustatOral substrate reduction therapy mainly used in type 1 disease. It is not established for neurological disease.
- MiglustatOral substrate reduction therapy that has been used when enzyme therapy is not suitable.
Bottom line for clinicians
Infilbray is for patients with neurological symptoms of Type 3 Gaucher disease. The sources supplied have no Gaucher disease trial, so efficacy in this population cannot be judged from them. Venglustat showed no benefit in ADPKD, where eGFR decline was faster than with placebo, or in GBA1-associated Parkinson's disease. Weigh the gastrointestinal effects and the limited long-term data, and check the full label and approval data.
Our coverage
We have not covered this drug yet.
Sources
- FDA list of novel approvals
- Gansevoort RT, et al. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. Am J Kidney Dis. 2023;81:517-527.e1.
- ClinicalTrials.gov NCT03523728
- Giladi N, et al. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2023;22:661-671.
- ClinicalTrials.gov NCT02906020
- Peterschmitt MJ, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. J Parkinsons Dis. 2022;12:557-570.
Dosing, contraindications and full warnings are in the prescribing information.
New FDA approvals in your inbox
The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.
Your subscription opens securely in a new tab.
Last updated November 19, 2026 by 2 Minute Medicine.
For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.